Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 3/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 3/20 | 0.41 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9890772 | 0.91 | CYP2C19 (0.45) | ICMTKCNA3CYP2C19DHODH | |
| SCHEMBL2395091 | 0.91 | CYP2C19 (0.49) | ICMTCYP2C19SIRT1NPC1 | |
| SCHEMBL2393249 | 0.87 | ICMT (0.45) | ICMTNPC1RAB9A | |
| SCHEMBL3735666 | 0.86 | FABP4 (0.45) | FABP4SHMT1FABP5DHODH | |
| SCHEMBL9890727 | 0.84 | FFAR1 (0.49) | BACE1CYP2C19FABP4SHMT1SIRT1 | |
| SCHEMBL2397285 | 0.84 | PSEN1 (0.48) | ICMTCYP2C19GCGRP2RX1 | |
| SCHEMBL9890780 | 0.84 | ICMT (0.50) | ICMTSHMT1 | |
| SCHEMBL9890771 | 0.81 | SHMT1 (0.47) | KCNA3FABP4SHMT1FABP5GCGR | |
| SCHEMBL2395113 | 0.81 | CHRM1 (0.45) | ICMTCYP2C19SHMT1 | |
| SCHEMBL9890778 | 0.79 | GRM2 (0.48) | ICMTCYP2C19SIRT1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | ICMT 2894/4885KCNA3 42/4885BACE1 2072/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | ICMT 2894/4885KCNA3 42/4885BACE1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.